Literature DB >> 9395308

The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells--signals emanating from the erythropoietin receptor.

U Klingmüller1.   

Abstract

Red blood cells arise continuously from pluripotent stem cells which mature and become functionally specialized upon commitment to the erythroid lineage. In mammals, the key regulator of this process is the hormone erythropoietin (EPO). Hormone binding to the cognate receptor, the erythropoietin receptor (EPO-R), causes receptor homodimerization and transiently triggers tyrosine phosphorylation within target cells. Although the EPO-R lacks intrinsic enzymatic activity it couples, presumably sequentially, to the protein tyrosine kinase receptor c-KIT and the cytosolic protein tyrosine kinase JAK2. Signaling through the EPO-R is promoted by tyrosine phosphorylation of the cytosolic domain and the recruitment of secondary signaling molecules such as the lipid kinase inositolphospholipid 3-kinase (phosphatidylinositol 3-kinase) and protein tyrosine phosphatase SHP-2 to the activated receptor. Complex formation of the activated EPO-R with the protein tyrosine phosphatase SHP-1 terminates signaling. In primary fetal liver cells redundant signals emanating from phosphotyrosine residues in the EPO-R support formation of erythroid colonies in vitro. However, since the last tyrosine residue in the cytosolic domain of the EPO-R, Y479, uniquely supports in the absence of other tyrosine residues an almost normal level of colony-forming unit-erythroid (CFU-E) colony formation, Y479 represents one of the key residues required in vivo for erythroid proliferation and differentiation. The signal emanating from Y479 involves sequential EPO-induced recruitment of phosphoinositol lipid 3-kinase to the EPO-R and activation of mitogen-activated-protein(MAP)kinase activity. The MAP-kinase signaling cascade could serve as an intracellular switch integrating signals mediated by several phosphotyrosine residues in the cytosolic domain of the EPO-R and provide a possible explanation for partial redundancy in signaling.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395308     DOI: 10.1111/j.1432-1033.1997.t01-1-00637.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  25 in total

1.  Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells.

Authors:  C Vitale; C Romagnani; A Puccetti; D Olive; R Costello; L Chiossone; A Pitto; A Bacigalupo; L Moretta; M C Mingari
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

2.  JAK2/STAT3/BMP-2 axis and NF-κB pathway are involved in erythropoietin-induced calcification in rat vascular smooth muscle cells.

Authors:  Jin He; Xiaoyi Zhong; Lin Zhao; Hua Gan
Journal:  Clin Exp Nephrol       Date:  2018-11-07       Impact factor: 2.801

3.  Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migration.

Authors:  Andrew C W Zannettino; Maria Roubelakis; Katie J Welldon; Denise E Jackson; Paul J Simmons; Linda J Bendall; Anthony Henniker; Kate L Harrison; Silvana Niutta; Kenneth F Bradstock; Suzanne M Watt
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

4.  8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.

Authors:  G Guasch; V Ollendorff; J P Borg; D Birnbaum; M J Pébusque
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition.

Authors:  Nilda L Alicea-Velázquez; Jean Jakoncic; Titus J Boggon
Journal:  J Struct Biol       Date:  2013-01-04       Impact factor: 2.867

6.  Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex.

Authors:  Yingxin L Zhang; Mala L Radhakrishnan; Xiaohui Lu; Alec W Gross; Bruce Tidor; Harvey F Lodish
Journal:  Mol Cell       Date:  2009-01-30       Impact factor: 17.970

7.  Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

Authors:  Geza Acs; Paul J Zhang; Cindy M McGrath; Peter Acs; John McBroom; Ahmed Mohyeldin; Suzhen Liu; Huasheng Lu; Ajay Verma
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

8.  The protective effect of erythropoietin on ischaemia/reperfusion injury of liver.

Authors:  Sezgin Yilmaz; Ersin Ates; Cigdem Tokyol; Turan Pehlivan; Serdar Erkasap; Tulay Koken
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

9.  Differential regulation of SOCS genes in normal and transformed erythroid cells.

Authors:  Mohinder K Sarna; Evan Ingley; Samantha J Busfield; Vanessa S Cull; Winald Lepere; David J McCarthy; Michael J Wright; Gene A Palmer; David Chappell; Melissa S Sayer; Warren S Alexander; Douglas J Hilton; Robyn Starr; Stephanie S Watowich; Thomas Bittorf; S Peter Klinken; Peta A Tilbrook
Journal:  Oncogene       Date:  2003-05-22       Impact factor: 9.867

Review 10.  Erythropoietin.

Authors:  W Jelkmann
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.